CGEM - NASDAQ

Cullinan Therapeutics, Inc.

CGEM·NASDAQ

$15.21

-0.85%

HealthcareMedical - Pharmaceuticals

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$934.78M

EPS-3.7200

P/E Ratio-4.09

Earnings Date08/06/2026

448.37M

Assets

-28%

3Y-20.0%

5Y+109.0%

10Y+1194.0%

39.64M

Total Liabilities

26%

3Y+52.0%

5Y+175.0%

10Y-28.0%

408.73M

Total Equity

-31%

3Y-24.0%

5Y+104.0%

10Y-2079.0%

Cullinan Therapeutics, Inc. Funding & Solvency Profile

CGEM · NASDAQ

Current Assets

Cash & Cash Equivalents88.33M

Net Receivables0.00

Inventory0.00

Other Current Assets8.86M

Total Current Assets387 M

Non-Current Assets

Property, Plant & Equipment3.05M

Goodwill & Intangible Assets0.00

Long-Term Investments58.27M

Other Non-Current Assets297.00K

Total Non-Current Assets62 M

Total Assets

448.37M

Financial Health Analysis

Current Ratio

10.25x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.10x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

349 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

86% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Cullinan Therapeutics, Inc. Balance Sheet

CGEM • NASDAQ

Cullinan Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	88.3M	83M	98.4M	156.2M	59.8M	168.2M	63.3M	33.8M
Short-Term Investments	289.6M	316M	368.6M	311.1M	230.7M	42M	35.4M	0.0
Cash & Short-Term Investments	377.9M	399M	467.1M	467.3M	290.5M	210.2M	98.6M	33.8M
Net Receivables	0.0	3M	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	0.0	3M	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	6.1M	2.1M	1.5M	387K
Other Current Assets	8.9M	12.7M	13.1M	7.2M	0.0	0.0	0.0	0.0
Total Current Assets	386.8M	414.7M	480.2M	474.5M	296.6M	212.3M	100.1M	34.2M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	3.1M	2.4M	3.5M	5.3M	77K	130K	182K	233K
Long-Term Investments	58.3M	204.4M	0.0	80.9M	140.4M	0.0	0.0	0.0
Other Non-Current Assets	297K	366K	459K	459K	147K	2.3M	188K	188K
Total Non-Current Assets	61.6M	207.2M	4M	86.6M	140.6M	2.4M	370K	421K
Total Assets	448.4M	621.8M	484.2M	561.1M	437.2M	214.7M	100.5M	34.6M
LIABILITIES
CURRENT LIABILITIES
Total Payables	841K	1.7M	10.4M	6.9M	3.2M	9.7M	934K	296K
Accounts Payable	841K	1.7M	2.5M	2.7M	3.2M	9.7M	934K	296K
Other Payables	0.0	0.0	7.9M	4.3M	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	26.2M	8.4M	12M	5M	2.9M	1.1M	1M
Short Term Debt	780K	0.0	0.0	178K	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	1.3M	1.4M	1.4M	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	4.3M	0.0	0.0	0.0	0.0
Other Current Liabilities	36.1M	1.4M	7.9M	2M	3.5M	1.8M	523K	27K
Total Current Liabilities	37.7M	30.6M	28.1M	22.5M	11.7M	14.3M	2.5M	1.3M
NON-CURRENT LIABILITIES
Long Term Debt	1.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	65K	74K	137.8M	54M
Total Non-Current Liabilities	1.9M	849K	2.2M	3.6M	65K	74K	137.8M	54M
Capital Lease Obligations	0.0	2.2M	3.6M	5M	0.0	0.0	0.0	0.0
Total Liabilities	39.6M	31.5M	30.3M	26.1M	11.8M	14.4M	140.4M	55.3M
SHAREHOLDERS' EQUITY
Common Stock	6K	6K	4K	5K	4K	3K	1K	1K
Additional Paid-In Capital	995.8M	958.7M	654.7M	585.3M	584.7M	292.3M	770K	214K
Retained Earnings	-588.1M	-368.2M	-200.9M	-47.7M	-158.9M	-93.3M	-41.5M	-20.9M
Accumulated Other Comprehensive Income/Loss	1M	-133K	-129K	-2.6M	-838K	-2K	-4K	0.0
Total Stockholders' Equity	408.7M	590.3M	453.7M	535M	425M	199M	-40.8M	-20.7M
Total Equity	408.7M	590.3M	453.9M	535M	425.4M	200.3M	-39.9M	-20.7M
Minority Interest	0.0	0.0	192K	0.0	403K	1.3M	864K	1K
SUMMARY
Total Liabilities & Equity	448.4M	621.8M	484.2M	561.1M	437.2M	214.7M	100.5M	34.6M
Total Investments	347.8M	520.4M	368.6M	392M	371.1M	42M	35.4M	0.0
Total Debt	2.7M	2.2M	3.6M	5.2M	0.0	0.0	0.0	0.0
Net Debt	-85.6M	-80.9M	-94.8M	-151M	-59.8M	-168.2M	-63.3M	-33.8M
Shares Outstanding	59,075,666	59,075,666	59,075,666	59,075,666	59,075,666	59,075,666	59,075,666	59,075,666

SEC Filings

CGEM - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 18, 2026	May 18, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	April 27, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 10, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 10, 2026	March 10, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 08, 2026	January 08, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 08, 2025	December 08, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 21, 2025	November 18, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 94 filings

Related Guides

Blog Categories

Continue your CGEM research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.